Literature DB >> 29616120

Salidroside induces apoptosis in human ovarian cancer SKOV3 and A2780 cells through the p53 signaling pathway.

Ge Yu1, Na Li2, Yan Zhao2, Wei Wang2, Xiao-Ling Feng1,2.   

Abstract

Salidroside is one of the most potent compounds extracted from the plant Rhodiola rosea, and its cardiovascular protective effects have been studied extensively. However, the role of salidroside in human ovarian carcinoma remains unknown. The aim of the current study was to investigate the effects of salidroside on the proliferation and apoptosis of SKOV3 and A2780 cells using MTT assay and acridine orange/ethidium bromide staining. Salidroside activated caspase-3 and upregulated the levels of apoptosis-inducing factor, Bcl-2-associated X and Bcl-2-associated death promoter (Bad) proteins. Furthermore, salidroside downregulated the levels of Bcl-2, p-Bad and X-linked inhibitor of apoptosis proteins. Salidroside activated the caspase-dependent pathway in SKOV3 and A2780 cells, upregulating p53, p21Cip1/Waf1 and p16INK4a. These results suggest that the p53/p21Cip1/Waf1/p16INK4a pathway may serve a key function in salidroside-mediated effects on SKOV3 and A2780 cells. The current findings indicate that salidroside may be a promising novel drug candidate for ovarian cancer therapy.

Entities:  

Keywords:  apoptosis; ovarian cancer; p53 signaling pathway; salidroside

Year:  2018        PMID: 29616120      PMCID: PMC5876432          DOI: 10.3892/ol.2018.8090

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  36 in total

1.  A double-blind, placebo-controlled pilot study of the stimulating and adaptogenic effect of Rhodiola rosea SHR-5 extract on the fatigue of students caused by stress during an examination period with a repeated low-dose regimen.

Authors:  A A Spasov; G K Wikman; V B Mandrikov; I A Mironova; V V Neumoin
Journal:  Phytomedicine       Date:  2000-04       Impact factor: 5.340

2.  Insulin receptor A and Sirtuin 1 synergistically improve learning and spatial memory following chronic salidroside treatment during hypoxia.

Authors:  Kalpana Barhwal; Saroj K Das; Ashish Kumar; Sunil K Hota; Ravi B Srivastava
Journal:  J Neurochem       Date:  2015-08-27       Impact factor: 5.372

Review 3.  The end of the (cell) line: methods for the study of apoptosis in vitro.

Authors:  A J McGahon; S J Martin; R P Bissonnette; A Mahboubi; Y Shi; R J Mogil; W K Nishioka; D R Green
Journal:  Methods Cell Biol       Date:  1995       Impact factor: 1.441

4.  Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy.

Authors:  M Friedlander; J Rau; C K Lee; W Meier; A Lesoin; J-W Kim; A Poveda; M Buck; G Scambia; M Shimada; F Hilpert; M T King; P Debruyne; A Bologna; S Malander; B J Monk; E Petru; P Calvert; T J Herzog; C Barrett; A du Bois
Journal:  Ann Oncol       Date:  2018-03-01       Impact factor: 32.976

5.  Andrographolide radiosensitizes human ovarian cancer SKOV3 xenografts due to an enhanced apoptosis and autophagy.

Authors:  Chao Zhang; Xingsheng Qiu
Journal:  Tumour Biol       Date:  2015-05-28

6.  KPNA2 is overexpressed in human and mouse endometrial cancers and promotes cellular proliferation.

Authors:  Kristian Ikenberg; Nadejda Valtcheva; Simone Brandt; Qing Zhong; Christine E Wong; Aurelia Noske; Markus Rechsteiner; Jan H Rueschoff; Rosmarie Caduff; Athanassios Dellas; Ellen Obermann; Daniel Fink; Thomas Fuchs; Wilhelm Krek; Holger Moch; Ian J Frew; Peter J Wild
Journal:  J Pathol       Date:  2014-07-30       Impact factor: 7.996

7.  Murine double minute 2 siRNA and wild-type p53 gene therapy enhances sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin chemotherapy in vitro and in vivo.

Authors:  Junlian Gu; Yufeng Tang; Yanan Liu; Hua Guo; Yue Wang; Lu Cai; Yang Li; Bo Wang
Journal:  Cancer Lett       Date:  2013-10-23       Impact factor: 8.679

8.  Salidroside reduces renal cell carcinoma proliferation by inhibiting JAK2/STAT3 signaling.

Authors:  Cai Lv; Yuan Huang; Zhen-Xiang Liu; Dan Yu; Zhi-Ming Bai
Journal:  Cancer Biomark       Date:  2016-06-07       Impact factor: 4.388

9.  Protective effects of salidroside on hydrogen peroxide-induced apoptosis in SH-SY5Y human neuroblastoma cells.

Authors:  Li Zhang; Huixin Yu; Yang Sun; Xiufeng Lin; Bo Chen; Chen Tan; Guoxian Cao; Zhengwu Wang
Journal:  Eur J Pharmacol       Date:  2007-02-15       Impact factor: 4.432

10.  Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer.

Authors:  E Sun Paik; Ji Hye Kim; Tae Joong Kim; Jeong Won Lee; Byoung Gie Kim; Duk Soo Bae; Chel Hun Choi
Journal:  J Gynecol Oncol       Date:  2018-01       Impact factor: 4.401

View more
  5 in total

Review 1.  Advances in Research on Anticancer Properties of Salidroside.

Authors:  An-Qi Sun; Xiu-Lian Ju
Journal:  Chin J Integr Med       Date:  2020-03-06       Impact factor: 1.978

2.  Loss of GINS2 inhibits cell proliferation and tumorigenesis in human gliomas.

Authors:  Yun-Long Shen; He-Zhen Li; Yan-Wei Hu; Lei Zheng; Qian Wang
Journal:  CNS Neurosci Ther       Date:  2018-10-18       Impact factor: 5.243

3.  Salidroside overcomes dexamethasone resistance in T-acute lymphoblastic leukemia cells.

Authors:  Ya-Na Niu; Yan Zeng; Fang-Fang Zhong; Si-Li Long; Dan-Wei Ren; Xiang Qin; Wen-Jun Liu
Journal:  Exp Ther Med       Date:  2021-04-15       Impact factor: 2.447

4.  Network Pharmacology-Based and Clinically Relevant Prediction of the Potential Targets of Chinese Herbs in Ovarian Cancer Patients.

Authors:  Jing Sun; Jinfeng Liu; Dan Liu; Xiongzhi Wu
Journal:  Biomed Res Int       Date:  2020-10-08       Impact factor: 3.411

5.  Glycosylation of anthocyanins enhances the apoptosis of colon cancer cells by handicapping energy metabolism.

Authors:  Nan Jing; Jiaxing Song; Zheng Liu; Luoyang Wang; Guoqiang Jiang
Journal:  BMC Complement Med Ther       Date:  2020-10-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.